Research indicated that individuals who were undergoing treatment with Egrifta SV (tesamorelin) experienced a decrease in abdominal fat after 26 weeks, in contrast to those who did not receive the medication. If you have been using Egrifta SV (tesamorelin) for 26 weeks without observing any changes in your belly fat, it is advisable to consult with your healthcare provider.